Canagliflozin use in Type I diabetes mellitus.

Postgrad Med

a Department of Emergency Medicine , The Ohio State University, Columbus , Ohio , USA.

Published: April 2017

Peters et al documented the appearance of diabetic ketoacidosis without significant elevation of serum glucose in patients treated with Canagliflozin. They solicited patient reports from their practice and from other colleagues' practices and identified nine patients, mainly with Type I Diabetes. Erondu et al evaluated the Canagliflozin development data base to describe the rate and appearance of ketoacidosis in the study patients. They found that in the research patients with Type 2 Diabetes, the rate of ketoacidosis in Canagliflozin patients was uncommon and similar to the reported rate in Type 2 patients not receiving Canagliflozin. Finally, Henry et al reported on a research program that added Canagliflozin onto insulin therapy in Type I patients, finding that there were only modest improvements in HgBA1 C levels and weight, while this therapy produced increased levels of ketosis and 6% rate of ketoacidosis in Canagliflozin patients. This information strongly suggests that Canagliflozin, and possibly the other SGLT-2 inhibitors, are not proper therapy for patients with Type I Diabetes.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00325481.2017.1264855DOI Listing

Publication Analysis

Top Keywords

type diabetes
16
patients type
12
patients
9
canagliflozin
8
rate ketoacidosis
8
ketoacidosis canagliflozin
8
canagliflozin patients
8
type patients
8
type
5
canagliflozin type
4

Similar Publications

Background: Each of the Coronavirus disease 2019 (COVID-19) vaccines has its characteristics that can affect their effectiveness in preventing hospitalization and patient mortality. The present study aimed to determine the effectiveness of COVID-19 vaccines, including whole-virus, protein-based, and vector-based on COVID-19 infection, hospitalization, and mortality.

Methods: The current cohort study was conducted using the data of all people who received at least two doses of each type of COVID-19 vaccine from March 2020 to August 2022 in Khorasan Rzavi province.

View Article and Find Full Text PDF

Activation of the De Novo Serine Synthesis Pathway and Disruption of Insulin Signaling Induced by Supplemental SeMet in Vitro.

Biol Trace Elem Res

January 2025

Department of Nutrition and Metabolism, Chinese Center for Disease Control and Prevention, National Institute for Nutrition and Health, Beijing, 100050, China.

Selenium (Se) intake or selenoprotein overexpression can cause abnormal glucose metabolism and increase the risk of type 2 diabetes (T2D). The purpose of this study is to observe whether glycolysis bypass in the de novo serine synthesis pathway (SSP) is activated under high-Se stress in vitro. Initially, HCT-116, L02, HepG2, and differentiated C2C12 cells were exposed to five selenomethionine (SeMet) concentrations (0.

View Article and Find Full Text PDF

Safety and effectiveness of dual therapy for Helicobacter pylori infection and the effect on the glycated hemoglobin level in type 2 diabetes.

Sci Rep

January 2025

Department of Gastroenterology, Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, 68 Gehu Middle Road, Wujing District, Changzhou, 213000, Jiangsu, China.

Patients with diabetes have a high risk of failure of H. pylori eradication therapy. The present study aims to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for the treatment of H.

View Article and Find Full Text PDF

Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study.

Sci Rep

January 2025

Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, P.O. Box: 13145-784, Tehran, Iran.

The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.

View Article and Find Full Text PDF

Divergent roles of mA in orchestrating brown and white adipocyte transcriptomes and systemic metabolism.

Nat Commun

January 2025

Section of Islet Cell and Regenerative Biology, Joslin Diabetes Center; Department of Medicine, BIDMC; Harvard Stem Cell Institute, Harvard Medical School, Boston, MA, USA.

N-methyladenosine (mA) is among the most abundant mRNA modifications, yet its cell-type-specific regulatory roles remain unclear. Here we show that mA methyltransferase-like 14 (METTL14) differentially regulates transcriptome in brown versus white adipose tissue (BAT and WAT), leading to divergent metabolic outcomes. In humans and mice with insulin resistance, METTL14 expression differs significantly from BAT and WAT in the context of its correlation with insulin sensitivity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!